Blog
12 Questions (Among Many) We'll Answer for You at 'Nuclear Cardiology Today'
Don't know where to turn for help with everyday practical dilemmas? Want help with the frustrating questions that plague daily practice but rarely, if ever, are addressed at annual conferences?
ASNC's Nuclear Cardiology Today: Practical Approaches to Real-World Practice was designed for you! Join Program Co-chairs Dennis Calnon, MD, MASNC, and David Wolinsky, MD, MASNC, April 17-19, 2020, in Washington, D.C., to get the answers to these and other questions:
ASNC's Nuclear Cardiology Today: Practical Approaches to Real-World Practice was designed for you! Join Program Co-chairs Dennis Calnon, MD, MASNC, and David Wolinsky, MD, MASNC, April 17-19, 2020, in Washington, D.C., to get the answers to these and other questions:
1 – Give it to me straight—will nuclear cardiology still be relevant in five years?
In this Friday afternoon keynote, “The Evolution of Evidence for Cardiac Imaging,” James Udelson, MD, MASNC, will get real on the role of nuclear cardiology today and in the future. 2 – The debate on PET Myocardial Blood Flow vs. CT-FFR is never-ending. Break it down for me -- which should I use?
Marcelo Di Carli, MD, MASNC, and Todd Villines, MD, will outline the merits of each approach.
3 – Is ischemic testing everuseful in asymptomatic patients?
Get some perspective from cases and other presentations by Dennis Calnon, MD, MASNC, and Khurram Nasir, MD.
4 – My patient's stress myocardial blood reserveis low because the resting myocardial blood flow is high. How should I include MBF in my MPI report?
Jamieson Bourque, MD, MHS, FASNC, will answer this challenging question in Sunday's “Practical Dilemmas in Nuclear Cardiology” session.
5 – The stress EKG is markedly abnormal, the perfusion scan is normal, and the patient is asymptomatic. What recommendation should be given to the referring doctor?
One more reason to attend NC Today's “Practical Dilemmas in Nuclear Cardiology” session on Sunday morning! Lawrence Phillips, MD, FASNC, will explain what to do in this situation.
6 – My patient has hereditary ATTR. His son had a positive genetic test and was referred for Tc-99m PYP testing that showed grade 1 uptake. How should we proceed?
Jamieson Bourque, MD, MHS, FASNC, will detail what he would do in this situation.
7 – My hospital is finally ready to buy a new camera. Should I ask for solid-state SPECT, SPECT/CT, or PET/CT?
In NC Today's opening session on Friday afternoon, Randall Thompson, MD, FASNC and Prem Soman, MD, MASNC, will walk you through the factors to consider before you buy.
8 – Despite my best efforts, my studies just don't look as good as the ones I see at conferences. How can I do a better study?
Edward Ficaro, PhD, FASNC, will explain exactly what the experts do to produce podium-worthy studies during “SPECT Is Here to Stay - So Do It Right!”on Friday afternoon.
9 – Are Tc-99m-PYP studies accurate enough to determine whether patients should proceed with expensive, disease-modifying therapy?
Jamieson Bourque, MD, MHS, FASNC, Prem Soman, MD, PhD, MASNC, and David Wolinsky, MD, MASNC, will outline what they look for in a Tc-99m PYP study before proceeding with treatment.
10 – Should every patient being evaluated for TAVR for aortic stenosis also be evaluated for cardiac amyloidosis? If that's even possible, how should we do it?
This is one of the crucial questions the David Wolinsky, MD, MASNC, will discuss during Sunday morning's “Practical Dilemmas in Nuclear Cardiology” session.
11 - Do CTA (and yes, even calcium scoring) have roles in evaluating patients with acute chest pain?
In Saturday afternoon's “Multimodality Imaging in Patients with CAD” session, you'll hear how leading health systems are navigating the ER to ensure patient safety while reducing unnecessary testing. Khurram Nasir, MD, will try to convince the audience that calcium scoring can be applied to patients with chest pain.
12 – We've waited for the ISCHEMIA trial results for so long! Now that we have them, how should the findings change how we use cardiac imaging?
Prem Soman, MD, PhD, MASNC, will answer this important question in his Sunday morning keynote, “Deciphering the ISCHEMIA trial.”
Have more questions you want answered? Take advantage of Nuclear Cardiology Today's highly interactive format. We've built plenty of time into the schedule for attendees to take the mic and outline their own practical dilemmas. You'll get input from our expert faculty as well as other attendees who may have tackled the same challenges you're facing now.